Las Vegas, NV November 8, 2005 ADDERALL XR (mixed salts of a single-entity amphetamine product) significantly improved driving performance, cognitive function and attention in young adults with attention-deficit/hyperactivity disorder (ADHD) in a controlled driving simulator study conducted by the Washington Neuropsychological Institute and presented today at the 18th Annual U.S. Psychiatric & Mental Health Congress in Las Vegas, NV.
"Adolescent and adult patients often fail to appreciate the effect that ADHD symptoms such as inattention have on daily activities such as driving," said Gary Kay, Ph.D., president of the Washington Neuropsychological Institute. "Our study demonstrates that ADDERALL XR helps young adults improve their ability to drive and do so safely over a 12-hour period."
Accidents are the leading cause of death until age 40. A study by Barkley et al published in 2002 demonstrated that adults with ADHD had a significant higher incidence of traffic violations, and license suspensions than patients without ADHD. This research suggested that ADHD patients were five times more likely than non-ADHD patients to have five or more speeding tickets and three times more likely to have had three or more vehicular crashes. Because of this data, Kay felt it was important to study the effect that ADDERALL XR, a major ADHD therapy, has on driving performance in young adult patients with ADHD.
Patients with ADHD taking ADDERALL XR demonstrated significant improvement in driving safety and performance, as measured by a 2.5 point reduction in their average Driving Safety Score (DSS), compared to 2.5 point gain among those on placebo (P<.005). The investigators determined the participants' DSS from mean scores derived from safety-related driving parameters, including speeding tickets, traffic tickets, crashes, crash avoidance rating, time to collision and excess speed, as presented on the STISIM DriveTM Simulation System at both testing Page: 1 2 3 Related medicine news :1
Contact: Sherry Goldberg
. Shire announces positive two-year study of ADDERALL XR in the treatment of adult ADHD2
. FDA expands indication for ADDERALL XR (CII) confirming safety and efficacy in adolescents3
. Trial stops after stroke and mortality significantly reduced by blood4
. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms5
. Full-term, low-birth-weight babies at significantly greater risk for early respiratory symptoms6
. Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis7
. New study: Pine bark significantly reduces endometriosis8
. Regular acupressure can significantly reduce agitated behavior in dementia9
. Health care expenditures significantly higher for children with obesity10
. Women with rheumatoid arthritis have significantly less chance of remission than men11
. Younger African American women at significantly higher risk for breast cancer